Manufacturer tablets have a named identity
The current Wegovy US page identifies a semaglutide pill and distinguishes it from injection presentations. It says the pill is not approved for adolescents with obesity. That is one example of why route and population matter. A shared ingredient name cannot justify transferring an injection’s approved population or every study finding to a tablet.
Provider listings have different formulations
Ro and Hers name branded oral products in their current offers. Mochi lists an oral semaglutide item, while LevelsRx depicts an oral liquid with a dropper. These are not interchangeable purchases merely because they avoid an injection. The exact prescription identity and approval status should be provided by the clinician and pharmacy.
Not every weight-management pill is a GLP-1
Noom’s pricing page also describes a metformin program and states that metformin is not FDA approved for weight loss. An oral catalog can therefore contain medicines from different classes and with different approved purposes. The product name and clinical explanation matter more than a broad pill or weight-loss heading.
Add the access fee to the medicine price
A branded-pill headline may exclude clinical membership. Hers and Ro explicitly separate these costs in the reviewed records. Noom’s branded access program excludes medication from its program charge. A meaningful comparison identifies the selected tablet and then combines the applicable care and medicine expenses, including later billing and renewal periods.
CoreAge’s featured offers are injection pathways
CoreAge’s reviewed semaglutide and tirzepatide offers are compounded medication pathways, not branded Wegovy tablets. Their appearance elsewhere on this publication should not be read as an oral-product listing. The commercial offer and an oral comparison remain separate. A clinician should explain the exact formulation being considered and the relevant benefits, risks and alternatives.
Read the actual offers
These reviews show the provider-specific context behind this guide.
Official sources
Public-page information checked October 1, 2026. Prices, availability and terms can change. We did not perform patient care or checkout.
- Weight Management for Adults with Obesity | Wegovy® (semaglutide) ↗Checked 2026-10-01 · official public source
- Weight Loss Program Pricing | Ro ↗Checked 2026-10-01 · official public source
- Weight Loss Care for Women, Built to Last | Hers ↗Checked 2026-10-01 · official public source
- Telehealth for Weight Loss, Hair Loss, Skin & More | Mochi Health ↗Checked 2026-10-01 · official public source
- LevelsRx | Sustainable weight loss, backed by science. ↗Checked 2026-10-01 · official public source
- Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs ↗Checked 2026-10-01 · official public source
- Semaglutide - CoreAge Rx ↗Checked 2026-10-01 · official public source
Another useful question
The GLP-1 bill: medicine, membership and the next charge →
Branded and compounded GLP-1 medicines are different products →